Product name
Pyrroles as Anti-Cancer and Anti-Inflammatory AgentsSummary
Pyrroles as COX-inhibitors show cytotoxic properties, compounds with anti-inflammatory and anti-cancer potential.Organization name
ipal GmbHProfile
The cyclooxygenase is the key enzyme of the prostaglandin biosynthesis that catalyses the conversion of arachidonic acid to prostaglandins. Two isoforms, COX- 1 and COX-2, are known. COX-2 inhibitors are used as anti-inflammatory agents. However, due to adverse cardiovascular side effects several products had to be withdrawn from the market. In recent years, cyclooxygenases were also discussed as new targets for anti-cancer drugs, since abnormally high levels of COX-2 protein were observed in several types of cancer.
Competitiveness
- Pyrroles effectively inhibit cyclooxygenases, especially COX-1 and/or
COX-2. - Cytotoxic properties which makes them suitable for treating inflammatory diseases and cancer.
- In addition, the structure can be modified that apart from cytotoxic properties the compounds show estrogenic effects (estrogen agonist).
- Possibly reduced adverse cardiovascular effect.
An international patent application has been filed.
Additional information is provided in the attached pdf.
The invention was made at Free University of Berlin, Germany and is offered by IPAL.
Contact
IPAL GmbH
Dr. Andreas Voigt
andreas.voigt(at)ipal.de
About IPAL
The ipal GmbH patent agency assesses and markets the inventions of scientists in the area of Life Sciences and Physics & Engineering from Charité-Universitätsmedizin (University Medicine), Robert Koch Institute, Deutsches Herzzentrum (German Heart Institute), Bundesanstalt für Materialprüfung (BAM - Federal Institute for Materials Research and Testing), the Zuse Institute as well as the Paul Ehrlich Institute, Langen and the Jacobs University Bremen. IPAL provides all of the services necessary - from the assessment of patentable technologies to a comprehensive patent protection all the way to the evaluation of sales returns potentials on the market and successful commercialisation through the use of licensing agreements.
Description File
06041_Pyrrole.pdf
print this page
